elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
radium-223
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Application
keyword
radium-223
RIS
0.007
(Research Intensity Score)
Papers
1644
Top papers
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
2022 · 259 citations
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
2025 · 44 citations
Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis
2025 · 32 citations
LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3
2024 · 38 citations
Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”
2021 · 196 citations
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial
2025 · 24 citations
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
2023 · 70 citations
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
2024 · 37 citations
Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
2023 · 69 citations
Newest papers
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer
2026 · 6 citations
Synthesis, Characterization, and Evaluation of Chelators for Radium-223
2026 · 2 citations
Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer.
2026 · 2 citations
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
2026 · 1 citations
Prognostic Factor Analysis and Nomogram Development in Castration-Resistant Prostate Cancer with Visceral Metastases for Future Radionuclide Therapy Selection
2026
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801)
2026
Meaningful Radiographic and Metabolic Response to Enzalutamide Plus Radium‐223 Therapy in Metastatic Castration‐Resistant Prostate Cancer With PSA ‐Discordant Progression: A Case Report
2026
Eine Neubewertung der Radium-223-Therapie
2026
Sequential therapy with radium-223 chloride and 177Lu-PSMA in patients with metastatic castration-resistant prostate cancer
2026
Browse all papers →
radium-223's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
radium-223's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link